Arbutus Biopharma Corp ABUS

Healthcare Biotechnology

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.

NDAQ:ABUS - Post by User

Arbutus Biopharma Corp

Bullboard Posts

Post by HARLEYDAVIDSON21on Jan 12, 2015 5:01pm

320 Views

Post# 23311178

About OnCore Biopharma

OnCore Biopharma, Inc. is a privately held biotechnology company focused on the research, development, and commercialization of therapies for the treatment of chronic Hepatitis B virus (HBV) infection. The Company was founded by former executives of Pharmasset, Inc., which was acquired by Gilead Sciences in January 2012. OnCore has assembled a portfolio of novel product candidates with unique mechanisms of action for the treatment of Hepatitis B and is focused on delivering a cure. It is widely believed that eradicating covalently closed circular DNA (cccDNA) in HBV-infected hepatocytes represents the ultimate solution for curing chronic Hepatitis B infected patients. OnCore is currently addressing an all-oral, permanent HBV cure by targeting cccDNA with the goal of achieving a "functional cure," wherein the risk of death from liver disease due to HBV is the same as a person with a naturally resolved infection. OnCore is combining agents against cccDNA with other novel direct acting antiviral mechanisms and strategies that engage host immune response. OnCore believes that combination therapy will be required to achieve complete eradication of HBV from the liver. OnCore is located at the Pennsylvania Biotechnology Center in Doylestown, Pennsylvania, which is also home to the Hepatitis B Foundation and the Foundation’s research center, the Baruch S. Blumberg Institute. For more information, please visitwww.oncorebiopharma.com . To be added to the Company's e-mail list to receive news directly, please send an email toir@oncorebiopharma.com .

Bullboard Posts

Level up your trading with BMO InvestorLine’s enhanced features